CA1323303C - Advanced anticancer therapy and cytotoxic medicaments for its implementation - Google Patents
Advanced anticancer therapy and cytotoxic medicaments for its implementationInfo
- Publication number
- CA1323303C CA1323303C CA000543912A CA543912A CA1323303C CA 1323303 C CA1323303 C CA 1323303C CA 000543912 A CA000543912 A CA 000543912A CA 543912 A CA543912 A CA 543912A CA 1323303 C CA1323303 C CA 1323303C
- Authority
- CA
- Canada
- Prior art keywords
- egf
- cytotoxic
- cells
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 230000001472 cytotoxic effect Effects 0.000 title claims abstract description 25
- 231100000433 cytotoxic Toxicity 0.000 title claims abstract description 23
- 238000011319 anticancer therapy Methods 0.000 title 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims abstract description 33
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims abstract description 33
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims abstract description 33
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 11
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 8
- 108010020346 Polyglutamic Acid Proteins 0.000 claims abstract description 6
- 229920001577 copolymer Polymers 0.000 claims abstract description 6
- 229920002643 polyglutamic acid Polymers 0.000 claims abstract description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 5
- 229920000805 Polyaspartic acid Polymers 0.000 claims abstract 2
- 108010064470 polyaspartate Proteins 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 98
- 150000001875 compounds Chemical class 0.000 claims description 64
- 230000003211 malignant effect Effects 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 17
- 229940024606 amino acid Drugs 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 239000002254 cytotoxic agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- -1 urogastrone Chemical compound 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 229940009456 adriamycin Drugs 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 238000006065 biodegradation reaction Methods 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000011275 oncology therapy Methods 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 108010066676 Abrin Proteins 0.000 claims description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 2
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 108010056028 auromycin Proteins 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000005859 cell recognition Effects 0.000 claims description 2
- 230000002121 endocytic effect Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960003569 hematoporphyrin Drugs 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 150000001510 aspartic acids Chemical class 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 150000002307 glutamic acids Chemical class 0.000 claims 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003057 platinum Chemical class 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract description 46
- 229940079593 drug Drugs 0.000 abstract description 23
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 14
- 229940125890 compound Ia Drugs 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 7
- 108060006698 EGF receptor Proteins 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 239000003080 antimitotic agent Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical group C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- VHYRLCJMMJQUBY-UHFFFAOYSA-N 1-[4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC1=CC=C(N2C(C=CC2=O)=O)C=C1 VHYRLCJMMJQUBY-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 101100388201 Pseudomonas fluorescens biotype C dsbE gene Proteins 0.000 description 1
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical group C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical compound NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
- 229950002705 arsanilic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000015246 common arrowhead Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP86810347 | 1986-08-07 | ||
| EP86810347.4 | 1986-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1323303C true CA1323303C (en) | 1993-10-19 |
Family
ID=8196463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000543912A Expired - Fee Related CA1323303C (en) | 1986-08-07 | 1987-08-06 | Advanced anticancer therapy and cytotoxic medicaments for its implementation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5087616A (en, 2012) |
| EP (1) | EP0259904B1 (en, 2012) |
| JP (1) | JPH01500435A (en, 2012) |
| AU (1) | AU608531B2 (en, 2012) |
| CA (1) | CA1323303C (en, 2012) |
| DE (1) | DE3770730D1 (en, 2012) |
| DK (1) | DK184788A (en, 2012) |
| FI (1) | FI881579A7 (en, 2012) |
| IN (1) | IN165717B (en, 2012) |
| WO (1) | WO1988000837A2 (en, 2012) |
Families Citing this family (310)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN165717B (en, 2012) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5529932A (en) * | 1988-01-28 | 1996-06-25 | Pharmacia, S.P.A. | Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis |
| IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| DE4004573A1 (de) * | 1989-02-17 | 1990-08-23 | Tanabe Seiyaku Co | Neues versuchstier und seine herstellung |
| US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5191067A (en) * | 1989-04-27 | 1993-03-02 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
| US5576288A (en) * | 1989-04-27 | 1996-11-19 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| EP0436005B1 (en) * | 1989-07-20 | 1995-03-29 | Sandoz Ltd. | Labeled polypeptide derivatives |
| US5208323A (en) * | 1989-08-10 | 1993-05-04 | Universite Laval | Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5632988A (en) * | 1989-10-23 | 1997-05-27 | Schering Corporation | Polypeptide inhibitors of gamma interferon |
| ES2155821T5 (es) * | 1990-03-02 | 2008-04-16 | Boston Medical Center Corporation | Toxinas quimericas mejoradas. |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| ATE115864T1 (de) * | 1990-05-30 | 1995-01-15 | Deutsches Krebsforsch | Polyethersubstituierte tumormittel. |
| IL98528A0 (en) * | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| AU657910B2 (en) * | 1990-07-05 | 1995-03-30 | Akzo N.V. | Receptor directed-toxin conjugates |
| US5478804A (en) * | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
| DE69126124T2 (de) * | 1990-09-28 | 1997-08-28 | Neorx Corp | Polymere träger zur freisetzung kovalent gebundener wirkstoffe |
| US5431899A (en) * | 1991-02-04 | 1995-07-11 | University Of Saskatchewan | Rotavirus VP6 as a diagnostic and targeting agent |
| US5464753A (en) * | 1991-03-08 | 1995-11-07 | Univ Illinois | Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression |
| DE69233069T2 (de) * | 1991-03-15 | 2003-11-27 | Amgen Inc., Thousand Oaks | Pegylation von polypeptiden |
| WO1992020371A1 (en) * | 1991-05-10 | 1992-11-26 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| ATE126066T1 (de) * | 1991-07-22 | 1995-08-15 | Bracco Int Bv | Anwendung von chelaten von konjugaten mit paramagnetischen metallen für targetting. |
| US5981273A (en) * | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells |
| US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5922859A (en) * | 1992-02-01 | 1999-07-13 | Boehringer Ingelheim International Gmbh | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells |
| DE69231123T2 (de) * | 1992-03-25 | 2001-02-15 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
| US5679350A (en) * | 1992-05-28 | 1997-10-21 | The University Of Toledo | Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material |
| DE69328092T2 (de) * | 1992-05-28 | 2000-07-20 | The University Of Toledo, Toledo | Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial |
| AU685058B2 (en) * | 1992-06-16 | 1998-01-15 | Selective Genetics, Inc. | Recombinant production of saporin-containing proteins |
| US5393737A (en) * | 1992-08-20 | 1995-02-28 | Health Research, Inc. | Cytotoxic drug conjugates for treatment of neoplastic diseases |
| ES2149823T3 (es) * | 1992-09-03 | 2000-11-16 | Univ California | Factor y composiciones que afectan al tejido dorsal. |
| US5466672A (en) * | 1992-12-04 | 1995-11-14 | Ophidian Pharmaceuticals, Inc. | Therapeutic use of clostridium difficile toxin A |
| ES2146649T3 (es) | 1993-05-05 | 2000-08-16 | Keith Rose | Compuestos de polioximas y su preparacion. |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5502037A (en) * | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
| US6491905B1 (en) * | 1993-09-14 | 2002-12-10 | The Uab Research Foundation | Recombinant bacterial cells for delivery of PNP to tumor cells |
| DE69425356T2 (de) * | 1993-09-22 | 2002-04-18 | Hoechst Ag | Pro-Prodrugs, ihre Herstellung und Anwendung |
| US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5962220A (en) * | 1993-10-26 | 1999-10-05 | Thomas Jefferson University | Compositions that specifically bind to colorectal cells and methods of using the same |
| CA2137639C (en) * | 1993-12-09 | 1999-01-26 | Agustin B. L. Davila | Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases |
| US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| US5911995A (en) * | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| DE4433890C2 (de) * | 1994-09-22 | 1999-02-18 | Deutsches Krebsforsch | Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein |
| JP3251294B2 (ja) * | 1994-11-10 | 2002-01-28 | ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデーション | 体内に薬剤を直接送出する、移植・補充可能な放出制御装置 |
| US5766899A (en) * | 1995-02-27 | 1998-06-16 | Board Of Regents , The University Of Texas System | Targeted nucleic acid delivery into liver cells |
| US6015555A (en) * | 1995-05-19 | 2000-01-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
| ATE234635T1 (de) * | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| US20050025740A1 (en) * | 1996-01-05 | 2005-02-03 | Keith Rose | Polyoxime compounds and their preparation |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| EA002400B1 (ru) | 1996-03-12 | 2002-04-25 | Пи Джи-Ти Экс Эл Компани, Л.П. | Водорастворимые пролекарства противоракового действия |
| US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| US5952294A (en) * | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US6080383A (en) * | 1997-01-13 | 2000-06-27 | Rose; Samuel | Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer |
| US5965118A (en) * | 1997-04-18 | 1999-10-12 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
| WO1998047496A2 (en) * | 1997-04-18 | 1998-10-29 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
| US6916790B2 (en) | 1997-05-05 | 2005-07-12 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis |
| EP0981545B1 (en) * | 1997-05-05 | 2006-09-13 | Mayo Foundation For Medical Education And Research | IGFIIE/ IGFBP2 complex |
| US6548482B1 (en) | 1997-05-05 | 2003-04-15 | Mayo Foundation For Medical Education And Research | Treatment of osteoporosis |
| US6030997A (en) * | 1998-01-21 | 2000-02-29 | Eilat; Eran | Acid labile prodrugs |
| US6866837B2 (en) | 1998-06-05 | 2005-03-15 | Mallinckrodt Inc. | Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors |
| US6747055B1 (en) | 1998-07-17 | 2004-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Water-soluble drugs and methods for their production |
| WO2000003737A2 (en) * | 1998-07-17 | 2000-01-27 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble drugs and methods for their production |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| GB9904582D0 (en) * | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US7018654B2 (en) * | 1999-03-05 | 2006-03-28 | New River Pharmaceuticals Inc. | Pharmaceutical composition containing an active agent in an amino acid copolymer structure |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
| US6706892B1 (en) | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
| US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US20020077290A1 (en) * | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
| ATE452989T1 (de) | 2000-03-27 | 2010-01-15 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung von krebszellen |
| KR100784120B1 (ko) | 2000-06-02 | 2007-12-12 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 에틸렌디시스테인(ｅｃ)-약물 접합체 |
| US6919425B2 (en) * | 2000-06-30 | 2005-07-19 | Board Of Regents, The University Of Texas System | Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| US7163918B2 (en) | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| CN1469735A (zh) * | 2000-10-16 | 2004-01-21 | ����˹��ҩ�﹫˾ | 米托蒽醌的脂质体制剂 |
| US8394813B2 (en) * | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US6906182B2 (en) | 2000-12-01 | 2005-06-14 | Cell Works Therapeutics, Inc. | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use |
| CU22999A1 (es) | 2001-12-04 | 2004-10-12 | Centro Inmunologia Molecular | Método de tratamiento de enfermedades malignas e infecciosas crónicas |
| US20030003048A1 (en) * | 2001-04-26 | 2003-01-02 | Chun Li | Diagnostic imaging compositions, their methods of synthesis and use |
| ES2334494T5 (es) | 2001-05-11 | 2013-05-29 | Ludwig Institute For Cancer Research Ltd. | Proteínas de unión específicas y usos de las mismas |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US7001991B2 (en) * | 2001-05-15 | 2006-02-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of bioaffecting compounds for the treatment of cancer |
| PL367244A1 (en) * | 2001-05-15 | 2005-02-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of viral infections |
| WO2003000711A1 (en) * | 2001-06-22 | 2003-01-03 | The University Of British Columbia | Antimitotic eleuthesides |
| US7375083B2 (en) * | 2003-09-30 | 2008-05-20 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
| US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| WO2003072046A2 (en) * | 2002-02-22 | 2003-09-04 | New River Pharmaceuticals Inc. | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20030109432A1 (en) * | 2001-12-10 | 2003-06-12 | Zuo William W. | Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| RU2196604C1 (ru) * | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| WO2003072735A2 (en) * | 2002-02-22 | 2003-09-04 | New River Pharmaceuticals Inc. | Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels |
| HUE038446T2 (hu) | 2002-09-20 | 2018-10-29 | Alpharma Pharmaceuticals Llc | Szekvesztráló alegység és releváns kompozíciók és módszerek |
| EP2316493A3 (en) * | 2002-11-07 | 2011-08-10 | Board of Regents, The University of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US7981667B2 (en) * | 2003-05-07 | 2011-07-19 | Indiana University Research And Technology Corporation | Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto |
| CA2527646C (en) * | 2003-05-29 | 2011-08-23 | New River Pharmaceuticals Inc. | Abuse resistant amphetamine compounds |
| US20070087959A1 (en) * | 2003-08-19 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of inducing biomineralization method of inducing bone regeneration and methods related thereof |
| US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| EP1694325A4 (en) | 2003-12-03 | 2009-03-25 | Univ New Jersey Med | Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses |
| PL1695991T3 (pl) * | 2003-12-10 | 2010-05-31 | Toudai Tlo Ltd | Koordynacyjny kompleks diaminocykloheksanu platyny (II) z blokowym kopolimerem zawierającym fragment poli(kwasu karboksylowego), oraz środek przeciw-nowotworowy zawierający ten kompleks |
| US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
| HUE037549T2 (hu) | 2004-04-07 | 2018-09-28 | Rinat Neuroscience Corp | Eljárások csontrákfájdalom kezelésére idegi növekedési faktor antagonista antitest beadásával |
| US8454927B2 (en) * | 2004-08-04 | 2013-06-04 | Crystalplex Corporation | Alloyed semiconductor nanocrystals |
| US20060036084A1 (en) * | 2004-08-04 | 2006-02-16 | Lianhua Qu | Conglomerated semiconductor nanocrystals |
| AU2006255938B2 (en) * | 2005-06-09 | 2011-05-12 | Nanocarrier Co., Ltd. | Process for production of polymerized coordination compound of platinum complex |
| RU2303997C2 (ru) * | 2005-09-27 | 2007-08-10 | Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" | Конъюгат, обладающий избирательным действием по отношению к раковым опухолям |
| WO2007055902A1 (en) * | 2005-11-03 | 2007-05-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides and methods of use for treating and preventing cancer |
| CN102125695B (zh) * | 2005-12-05 | 2014-02-19 | 日东电工株式会社 | 聚谷氨酸盐-氨基酸轭合物及方法 |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US9107863B2 (en) * | 2006-03-27 | 2015-08-18 | The Buck Institute For Age Reasearch | Reagents and methods for cancer treatment and prevention |
| US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| RU2317102C1 (ru) * | 2006-05-31 | 2008-02-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Пептид, являющийся аналогом фрагмента альфа-фетопротеина, конъюгат пептида с доксорубицином и фармацевтическая композиция на его основе для лечения онкологических заболеваний |
| RU2445077C2 (ru) | 2006-06-19 | 2012-03-20 | АЛФАРМА, Инк. | Фармацевтические композиции |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| JP5399255B2 (ja) | 2006-10-31 | 2014-01-29 | アメリカ合衆国 | スムースンドポリペプチドおよび使用方法 |
| US8216565B2 (en) * | 2007-01-12 | 2012-07-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | GP100-specific T cell receptors and related materials and methods of use |
| EP2126127B1 (en) * | 2007-01-25 | 2016-09-28 | Dana-Farber Cancer Institute, Inc. | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
| ES2542152T3 (es) | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| EP2144631A2 (en) * | 2007-04-10 | 2010-01-20 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
| PT2155255E (pt) * | 2007-05-09 | 2013-10-15 | Nitto Denko Corp | Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido |
| WO2008141110A2 (en) * | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| WO2008141111A2 (en) * | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polymers conjugated with platinum drugs |
| CA2696360C (en) | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
| AU2008292910A1 (en) * | 2007-08-31 | 2009-03-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for inhibiting Wip1, prodrugs and compositions thereof, and related methods |
| RU2010137032A (ru) * | 2008-03-06 | 2012-04-20 | Нитто Денко Корпорейшн (Jp) | Конъюгаты паклитаксела с полимером и способы лечения рака |
| WO2010075417A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Survivin specific t cell receptor for treating cancer |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| WO2010106544A1 (en) * | 2009-03-16 | 2010-09-23 | Rajah Vijay Kumar | A method and apparatus for - focused resonance nanopermeabilization (forn) |
| CN102448482A (zh) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法 |
| US8603814B2 (en) | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
| US9849146B2 (en) | 2009-07-20 | 2017-12-26 | Rutgers, The State University Of New Jersey | Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A |
| WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CN102666845B (zh) | 2009-10-16 | 2015-06-10 | 不列颠哥伦比亚大学 | 磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法 |
| US20120208762A1 (en) | 2009-10-27 | 2012-08-16 | The Board Of Trustees Of The University Of Illinois | Methods of Diagnosing Diastolic Dysfunction |
| WO2011060218A1 (en) | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulated programmed death ligand-1 |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| CN102834108A (zh) | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
| EP2619223B1 (en) | 2010-09-21 | 2019-04-10 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-ssx-2 t cell receptors and related materials and methods of use |
| WO2012054825A1 (en) | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| EP2655401B1 (en) | 2010-12-20 | 2016-03-09 | The Regents of the University of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| MA34885B1 (fr) | 2010-12-22 | 2014-02-01 | Indiana Unversity Res And Technology Corp | Analogues du glucagon presentant una ctivite de recepteur de gip |
| CN102675422B (zh) | 2011-03-15 | 2014-02-05 | 天津托普泰克生物科技有限公司 | 抗乙型肝炎病毒x蛋白多肽药物 |
| CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| CN102746378B (zh) | 2011-04-22 | 2014-10-22 | 天津托普泰克生物科技有限公司 | 抗脂肪酸合成酶多肽及其应用 |
| CA2838013C (en) | 2011-06-09 | 2023-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes |
| EP2723367B1 (en) | 2011-06-22 | 2017-05-03 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| SI3392270T1 (sl) | 2011-09-15 | 2020-12-31 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni MAGE |
| EP3301110A1 (en) | 2011-09-16 | 2018-04-04 | The USA, as represented by The Secretary, Department of Health and Human Services | Pseudomonas exotoxin a with less immunogenic b cell epitopes |
| RU2644243C2 (ru) | 2011-10-20 | 2018-02-08 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы к cd22 |
| US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| NZ700362A (en) | 2012-04-11 | 2016-09-30 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| EP2852613B1 (en) | 2012-05-22 | 2019-01-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Murine anti-ny-eso-1 t cell receptors |
| SG11201408347UA (en) | 2012-06-14 | 2015-01-29 | Ambrx Inc | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| SI2864350T1 (en) | 2012-06-21 | 2018-08-31 | Indiana University Research And Technology Corporation | GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR |
| US9879065B2 (en) | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| CN104822705B (zh) | 2012-10-24 | 2019-07-12 | 美国卫生和人力服务部 | M971嵌合抗原受体 |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| CN105452288B (zh) | 2013-07-15 | 2019-08-13 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| WO2015051199A2 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| CA2932424C (en) | 2013-12-06 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| CN113046312A (zh) | 2014-04-23 | 2021-06-29 | 朱诺治疗学股份有限公司 | 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法 |
| CN106661098B (zh) | 2014-05-29 | 2021-05-04 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e7的t细胞受体 |
| KR102668549B1 (ko) | 2014-06-02 | 2024-05-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Cd19를 표적화하는 키메라 항원 수용체 |
| ES2959683T3 (es) | 2014-07-15 | 2024-02-27 | Juno Therapeutics Inc | Células manipuladas para terapia celular adoptiva |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107106610A (zh) | 2014-10-20 | 2017-08-29 | 朱诺治疗学股份有限公司 | 用于过继细胞治疗中的给药的组合物和方法 |
| WO2016071343A1 (en) | 2014-11-03 | 2016-05-12 | Immures S.R.L. | T cell receptors |
| ES2987570T3 (es) | 2014-11-05 | 2024-11-15 | Juno Therapeutics Inc | Métodos para la transducción y el procesamiento de células |
| AU2015358400B2 (en) | 2014-12-03 | 2020-09-10 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| NZ733841A (en) | 2015-01-16 | 2024-01-26 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for ror1 |
| WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
| EP3303586A1 (en) | 2015-05-29 | 2018-04-11 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| CN116875635A (zh) | 2015-10-22 | 2023-10-13 | 朱诺治疗学有限公司 | 用于转导的方法、反应剂盒、反应剂和设备 |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| MA44314A (fr) | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées |
| WO2017079703A1 (en) | 2015-11-05 | 2017-05-11 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| JP7184645B2 (ja) | 2015-12-03 | 2022-12-06 | ジュノー セラピューティクス インコーポレイテッド | 修飾キメラ受容体ならびに関連する組成物および方法 |
| EP4012415A3 (en) | 2015-12-04 | 2022-12-07 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| WO2017161212A1 (en) | 2016-03-16 | 2017-09-21 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| US20190287013A1 (en) | 2016-03-16 | 2019-09-19 | Juno Therapeutics, Inc. | Methods for determining dosing of a therapeutic agent and related treatments |
| MX2018011480A (es) | 2016-03-22 | 2019-03-28 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Metodos de intervencion temprana para prevenir o aminorar toxicidad. |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| IL302641A (en) | 2016-05-06 | 2023-07-01 | Juno Therapeutics Inc | Genetically Engineered Cells and Methods of Making the Same |
| EP3464366A1 (en) | 2016-05-27 | 2019-04-10 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
| WO2017210689A1 (en) | 2016-06-03 | 2017-12-07 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| WO2018005759A1 (en) | 2016-07-01 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection |
| US12304935B2 (en) | 2016-07-29 | 2025-05-20 | Juno Therapeutics, Inc. | Immunomodulatory polypeptides and related compositions and methods |
| JP2019536437A (ja) | 2016-10-03 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| AU2017367695A1 (en) | 2016-12-02 | 2019-06-13 | Juno Therapeutics, Inc. | Engineered B cells and related compositions and methods |
| CN110290807B (zh) | 2016-12-03 | 2024-06-14 | 朱诺治疗学股份有限公司 | 确定car-t细胞给药的方法 |
| MX2019006285A (es) | 2016-12-03 | 2019-12-16 | Juno Therapeutics Inc | Metodos para modulacion de celulas cart-t. |
| CA3045338A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| US11821027B2 (en) | 2017-01-10 | 2023-11-21 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
| EP3571221A2 (en) | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| CA3056261A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111201438A (zh) | 2017-06-02 | 2020-05-26 | 朱诺治疗学股份有限公司 | 与和细胞疗法相关的毒性有关的制品和方法 |
| CN109517820B (zh) | 2017-09-20 | 2021-09-24 | 北京宇繁生物科技有限公司 | 一种靶向HPK1的gRNA以及HPK1基因编辑方法 |
| MX2020003536A (es) | 2017-10-03 | 2020-09-14 | Juno Therapeutics Inc | Moleculas de union especifica a virus de papiloma humano (hpv). |
| SG11202003657VA (en) | 2017-11-01 | 2020-05-28 | Juno Therapeutics Inc | Process for producing a t cell composition |
| CA3081456A1 (en) | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| CN111902159A (zh) | 2017-11-01 | 2020-11-06 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体 |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| JP7256197B2 (ja) | 2017-11-01 | 2023-04-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原に特異的な抗体およびキメラ抗原受容体 |
| JP2021502077A (ja) | 2017-11-06 | 2021-01-28 | エディタス・メディシン，インコーポレイテッド | 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素 |
| EP3716980A1 (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| CN112203680A (zh) | 2017-12-08 | 2021-01-08 | 朱诺治疗学股份有限公司 | 用于细胞疗法的表型标记和相关方法 |
| US20200384025A1 (en) | 2017-12-08 | 2020-12-10 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| US20210207080A1 (en) | 2017-12-08 | 2021-07-08 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| JP2021506260A (ja) | 2017-12-15 | 2021-02-22 | ジュノー セラピューティクス インコーポレイテッド | 抗ｃｃｔ５結合分子およびその使用方法 |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| US20210069246A1 (en) | 2018-01-31 | 2021-03-11 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| EP3762012A1 (en) | 2018-03-09 | 2021-01-13 | Ospedale San Raffaele S.r.l. | Il-1 antagonist and toxicity induced by cell therapy |
| JP7630280B2 (ja) | 2018-04-05 | 2025-02-17 | ジュノー セラピューティクス インコーポレイテッド | 組換え受容体を発現するｔ細胞、関連ポリヌクレオチド、および方法 |
| KR20210029707A (ko) | 2018-04-05 | 2021-03-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물 |
| EP3773908A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| US20210163893A1 (en) | 2018-08-09 | 2021-06-03 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| JP7538109B2 (ja) | 2018-08-09 | 2024-08-21 | ジュノー セラピューティクス インコーポレイテッド | 組み込まれた核酸を評価するための方法 |
| WO2020043899A1 (en) | 2018-08-31 | 2020-03-05 | Invectys | Chimeric antigen receptors against multiple hla-g isoforms |
| AU2019370705A1 (en) | 2018-10-31 | 2021-05-27 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| KR20210113169A (ko) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법 |
| MA54079A (fr) | 2018-11-01 | 2021-09-08 | Juno Therapeutics Inc | Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g) |
| US20210393691A1 (en) | 2018-11-06 | 2021-12-23 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| IL283218B1 (en) | 2018-11-16 | 2025-07-01 | Juno Therapeutics Inc | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| PT3886894T (pt) | 2018-11-30 | 2024-05-02 | Juno Therapeutics Inc | Métodos para dosagem e tratamento de malignidades de células b em terapia celular adotiva |
| PL3886875T3 (pl) | 2018-11-30 | 2024-09-09 | Juno Therapeutics, Inc. | Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej |
| JP7678753B2 (ja) | 2019-01-29 | 2025-05-16 | ジュノー セラピューティクス インコーポレイテッド | 受容体チロシンキナーゼ様オーファン受容体１（ｒｏｒ１）に特異的な抗体およびキメラ抗原受容体 |
| CA3136618A1 (en) | 2019-04-10 | 2020-10-15 | Elevatebio Technologies, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| US12404331B2 (en) | 2019-04-19 | 2025-09-02 | Tcrcure Biopharma Corp. | Anti-PD-1 antibodies and uses thereof |
| US20220218750A1 (en) | 2019-05-01 | 2022-07-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| MA55811A (fr) | 2019-05-01 | 2022-03-09 | Editas Medicine Inc | Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés |
| EP3972653A1 (en) | 2019-05-22 | 2022-03-30 | Massachusetts Institute of Technology | Circular rna compositions and methods |
| CN112390894A (zh) | 2019-08-12 | 2021-02-23 | 广东东阳光药业有限公司 | 嵌合抗原受体及其应用 |
| EP4051402A1 (en) | 2019-10-30 | 2022-09-07 | Juno Therapeutics GmbH | Cell selection and/or stimulation devices and methods of use |
| BR112022010310A2 (pt) | 2019-12-06 | 2022-08-16 | Juno Therapeutics Inc | Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b |
| EP4097218A1 (en) | 2020-01-28 | 2022-12-07 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| JP2023522857A (ja) | 2020-04-10 | 2023-06-01 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用 |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| BR112022023554A2 (pt) | 2020-05-19 | 2023-04-11 | Orna Therapeutics Inc | Composições e métodos de rna circular |
| KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| CN117321417A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 确定治疗性细胞组合物的效力的方法 |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| CN115404240A (zh) | 2021-05-28 | 2022-11-29 | 上海环码生物医药有限公司 | 制备环形rna的构建体、方法及其用途 |
| KR20240112994A (ko) | 2021-11-03 | 2024-07-19 | 셀진 코포레이션 | 골수종을 치료하는 데 사용하기 위한 b-세포 성숙 항원에 특이적인 키메라 항원 수용체 |
| MX2024005521A (es) | 2021-11-08 | 2024-05-21 | Orna Therapeutics Inc | Composiciones de nanoparticulas de lipidos para la administracion de polinucleotidos circulares. |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| US20250161359A1 (en) | 2022-02-22 | 2025-05-22 | Juno Therapeutics, Inc. | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4532731A2 (en) | 2022-05-30 | 2025-04-09 | Shanghai Circode Biomed Co., Ltd | Synthetic circular rna compositions and methods of use thereof |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| EP4547230A1 (en) | 2022-06-29 | 2025-05-07 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids |
| IL318416A (en) | 2022-08-05 | 2025-03-01 | Juno Therapeutics Inc | Chimeric antigen receptors specific for GPRC5D and BCMA |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| WO2024129982A2 (en) | 2022-12-15 | 2024-06-20 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024233308A2 (en) | 2023-05-05 | 2024-11-14 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2025007148A1 (en) | 2023-06-30 | 2025-01-02 | Orna Therapeutics, Inc. | Polymer lipid nanoparticle compositions for delivering circular polynucleotides |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076472A1 (en) | 2023-10-06 | 2025-04-10 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025117969A1 (en) | 2023-12-01 | 2025-06-05 | Orna Therapeutics, Inc. | Process for manufacturing lipid nanoparticles |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE38892B1 (en) * | 1973-03-28 | 1978-06-21 | Ici Ltd | Pharmaceutical compositions |
| EP0040506B1 (en) * | 1980-05-21 | 1986-08-20 | Teijin Limited | Reactive polymer and process for the preparation thereof |
| DK339781A (da) * | 1980-08-05 | 1982-02-06 | Searle & Co | Syntetisk gen |
| EP0108132A1 (en) * | 1982-05-06 | 1984-05-16 | Applied Molecular Genetics Inc. | The manufacture and expression of genes for urogastrone and polypeptide analogs thereof |
| US4587046A (en) * | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
| JPS58219124A (ja) * | 1982-06-15 | 1983-12-20 | Nippon Chem Res Kk | ヒト上皮細胞増殖因子の製造法 |
| US4485093A (en) * | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
| JPS59116232A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体及びその製造法 |
| IL71991A (en) * | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| WO1985000369A1 (en) * | 1983-07-05 | 1985-01-31 | Chiron Corporation | Hybrid dna synthesis of epidermal growth factor |
| JPS6028994A (ja) * | 1983-07-08 | 1985-02-14 | Wakunaga Seiyaku Kk | 〔２１―ロイシン〕ヒトウロガストロン |
| IL69719A0 (en) * | 1983-09-14 | 1983-12-30 | Yeda Res & Dev | Synthetic peptides with egf like activity |
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| US4522750A (en) * | 1984-02-21 | 1985-06-11 | Eli Lilly And Company | Cytotoxic compositions of transferrin coupled to vinca alkaloids |
| US4670563A (en) * | 1984-06-20 | 1987-06-02 | Sanofi | Imidazolides as intermediates for the synthesis of cytotoxic conjugates |
| IN165717B (en, 2012) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute |
-
1987
- 1987-07-29 IN IN543/MAS/87A patent/IN165717B/en unknown
- 1987-08-05 DE DE8787201490T patent/DE3770730D1/de not_active Expired - Fee Related
- 1987-08-05 AU AU77887/87A patent/AU608531B2/en not_active Expired - Fee Related
- 1987-08-05 WO PCT/EP1987/000435 patent/WO1988000837A2/en active Application Filing
- 1987-08-05 JP JP62504770A patent/JPH01500435A/ja active Pending
- 1987-08-05 FI FI881579A patent/FI881579A7/fi not_active IP Right Cessation
- 1987-08-05 EP EP87201490A patent/EP0259904B1/en not_active Expired - Lifetime
- 1987-08-06 CA CA000543912A patent/CA1323303C/en not_active Expired - Fee Related
- 1987-08-06 US US07/082,244 patent/US5087616A/en not_active Expired - Fee Related
-
1988
- 1988-04-06 DK DK184788A patent/DK184788A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IN165717B (en, 2012) | 1989-12-23 |
| US5087616A (en) | 1992-02-11 |
| FI881579L (fi) | 1988-04-06 |
| DE3770730D1 (de) | 1991-07-18 |
| AU7788787A (en) | 1988-02-24 |
| EP0259904A1 (en) | 1988-03-16 |
| EP0259904B1 (en) | 1991-06-12 |
| DK184788A (da) | 1988-06-06 |
| JPH01500435A (ja) | 1989-02-16 |
| AU608531B2 (en) | 1991-04-11 |
| WO1988000837A3 (en) | 1988-03-10 |
| FI881579A0 (fi) | 1988-04-06 |
| DK184788D0 (da) | 1988-04-06 |
| WO1988000837A2 (en) | 1988-02-11 |
| FI881579A7 (fi) | 1988-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1323303C (en) | Advanced anticancer therapy and cytotoxic medicaments for its implementation | |
| Duncan et al. | Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats | |
| EP0701448B1 (en) | Amplification of the vitamin b 12 uptake system using polymers | |
| US5548064A (en) | Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions | |
| US7060498B1 (en) | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers | |
| EP0187547B1 (en) | Synthetic polymeric drugs | |
| AU750387B2 (en) | Novel conjugates of opioids and endogenous carriers | |
| CA2128330A1 (en) | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light | |
| NZ276943A (en) | Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation | |
| JP2002543111A (ja) | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 | |
| JPH07508727A (ja) | 生体分子と結合したポリオキシメチレン−オキシエチレン共重合体 | |
| Nori et al. | Subcellular trafficking of HPMA copolymer–Tat conjugates in human ovarian carcinoma cells | |
| Van Heeswijk et al. | The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin. Part I | |
| EP1463529B1 (en) | Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy | |
| MXPA01013276A (es) | Materiales biologicamente activos. | |
| Ryser et al. | Drug-poly (lysine) conjugates: their potential for chemotherapy and for the study of endocytosis | |
| JPS62167800A (ja) | オシド単位の酸化およびシツフ塩基の形成により変性されたリボソ−ム不活性化糖タンパク、およびこの糖タンパクを含む生体内持続性免疫毒素 | |
| Franchini et al. | Perspectives on: Recent advances in poly (amidoamine) s chemistry | |
| US20050220754A1 (en) | Vitamin directed targeting therapy | |
| Hoes et al. | Design of soluble conjugates of biodegradable polymeric carriers and adriamycin | |
| SK278506B6 (en) | THE POLYMERIC DRUG AND PREPARATION METHOD THEREOF m cells. | |
| JPS62175500A (ja) | 修飾糖タンパク質、当該修飾糖タンパク質の製造方法、当該修飾糖タンパク質を含む免疫毒素および当該免疫毒素を有効成分として含む抗ガン剤組成物 | |
| Maree et al. | Synthesis and Anchoring of Antineoplastic Ferrocene and Phthalocyanine Derivatives on Water‐Soluble Polymeric Drug Carriers Derived from Lysine and Aspartic Acid | |
| Lloyd et al. | Targeting and lysosomal handling of polymethacrylamide-oligopeptide conjugates | |
| Fenili | NOVEL BIOACTIVE AND BIODEGRADABLE BIOMATERIALS OF POLY (AMIDOMINE) STRUCTURE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |